Biochip tests blood on the spot
UC BERKELEY (US) — A self-powered lab-on-a-chip that works without extra tubes or components could be a boon for global health care.
“The dream of a true lab-on-a-chip has been around for a while, but most systems developed thus far have not been truly autonomous,” says Ivan Dimov, a postdoctoral researcher working in the lab of Luke Lee, professor of bioengineering at University of California, Berkeley and co-lead author of the international study.
“By the time you add tubing and sample prep setup components required to make previous chips function, they lose their characteristic of being small, portable and cheap. In our device, there are no external connections or tubing required, so this can truly become a point-of-care system.”
The research findings are reported in the journal Lab on a Chip.
“This is a very important development for global healthcare diagnostics,” says Lee. “Field workers would be able to use this device to detect diseases such as HIV or tuberculosis in a matter of minutes.
“The fact that we reduced the complexity of the biochip and used plastic components makes it much easier to manufacture in high volume at low cost. Our goal is to address global health care needs with diagnostic devices that are functional, cheap, and truly portable.”
The Self-powered Integrated Microfluidic Blood Analysis System (SIMBAS) biochip takes advantage of the laws of microscale physics to speed up processes that may take hours or days in a traditional lab.
The SIMBAS biochip uses trenches patterned underneath microfluidic channels that are about the width of a human hair. When whole blood is dropped onto the chip’s inlets, the relatively heavy red and white blood cells settle down into the trenches, separating from the clear blood plasma. The blood moves through the chip in a process called degas-driven flow.
For degas-driven flow, air molecules inside the porous polymeric device are removed by placing the device in a vacuum-sealed package. When the seal is broken, the device is brought to atmospheric conditions, and air molecules are reabsorbed into the device material. This generates a pressure difference, which drives the blood fluid flow in the chip.
Researchers were able to capture more than 99 percent of the blood cells in the trenches and selectively separate plasma using this method.
“This prep work of separating the blood components for analysis is done with gravity, so samples are naturally absorbed and propelled into the chip without the need for external power,” says Dimov.
The proof-of-concept of SIMBAS was demonstrated by placing into the chip’s inlet a 5-microliter sample of whole blood that contained biotin (vitamin B7) at a concentration of about 1 part per 40 billion.
“That can be roughly thought of as finding a fine grain of sand in a 1,700-gallon sand pile,” Dimov says. The biodetectors in the SIMBAS chip provided a readout of the biotin levels in 10 minutes.
“Imagine if you had something as cheap and as easy to use as a pregnancy test, but that could quickly diagnose HIV and TB,” says Benjamin Ross, a UC Berkeley graduate student in bioengineering and study co-author. “That would be a real game-changer. It could save millions of lives.”
“The SIMBAS platform may create an effective molecular diagnostic biochip platform for cancer, cardiac disease, sepsis, and other diseases in developed countries as well,” Lee says.
Researchers at Dublin City University and École Polytechnique Fédérale de Lausanne (EPFL Switzerland) contributed to the study, that was funded the Science Foundation Ireland and the U.S. National Institutes of Health.
More news from UC Berkeley: http://newscenter.berkeley.edu/